According to leaked reports, China’s Ministry of Human Resources and Social Security (MoHRSS) is planning to announce 300 additions to the National Reimbursement Drug List (NRDL), which is a list of drugs covered under the country’s national insurance plan. The NRDL has not been updated since 2009, and an estimated 130 modern drugs will be added to the list. The remaining products will be traditional Chinese medicines. A number of oncology drugs are expected to be added to the list, as well as drugs from MNC companies like GlaxoSmithKline and AstraZeneca. It is still unknown when the MoHRSS will make its official announcement.